# Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)

> **NCT00365209** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Healthy, no Evidence of Disease
- Tobacco Use Disorder

## Interventions

- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **DRUG:** curcumin

## Key facts

- **NCT ID:** NCT00365209
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-09
- **Final completion:** 2011-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2015-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365209, "Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00365209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*